Alkermes plc announces agreement to acquire avadel pharmaceuticals plc

Not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction this announcement is being made pursuant to rule 2.7 of the irish takeover rules   —     augments revenue growth profile and diversifies alkermes' commercial portfolio with new high growth product, lumryz™(sodium oxybate) —     accelerates alkermes' commercial entry into sleep medicine market and provides strong foundation for potential launch of alixorexton —     expected to be immediately accretive and enhance profitability upon closing —     positions the combined organization to accelerate innovation and expand its leadership in development of treatments for sleep disorders and other neurological disorders —     transaction valued at $18.50 per share in cash with a cvr for an additional $1.50 per share in cash, for total consideration of up to $20.00 per share, or a transaction value of up to $2.1 billion —     alkermes to host conference call and webcast on oct. 22, 2025 at 8:00 a.m. et dublin , oct. 22, 2025 /prnewswire/ -- alkermes plc (nasdaq: alks) ("alkermes") and avadel pharmaceuticals plc (nasdaq: avdl) ("avadel") today announced that the companies have entered into a definitive agreement under which alkermes will acquire avadel, a commercial-stage biopharmaceutical company, for total transaction consideration of up to $20.00 per share in cash, which values avadel at approximately $2.1 billion and represents a premium of 38% to the weighted average trading price of avadel over the three months prior to today's announcement and a premium of 12% to avadel's closing price on oct. 21, 2025 (being the last business day prior to publication of this announcement).
AVDL Ratings Summary
AVDL Quant Ranking